

6042 Cornerstone Court W, Ste B San Diego, CA 92121

Tel: 1.858.202.1401 Fax: 1.858.481.8694 Email: info@bpsbioscience.com

## **Data Sheet**

# Spike S1 Neutralizing Antibody (SARS-CoV-2) (Clone: 414-1)

SARS-CoV-2, Monoclonal

Catalog #: 100793

**Lot #:** 200617 **Conc.:** 1.0 mg/ml

#### **Host Species | Isotype:**

Human | IgG1

Formulated in: 140 mM HEPES, pH 7.5, 70 mM NaCl, 32 mM NaOAc, 0.035% sodium azide, and 30% glycerol.

**<u>Stability</u>**: Stable for at least 12 months at -20°C. Avoid freeze/thaw cycles.

#### References:

- 1. Zhou P., et al., Nature. 2020; **579:** 270-289.
- 2. Xiao X., et al., Cell Mol Life Sci. 2004; 61(19-20): 2428-2430.


<u>Description</u>: Recombinant human monoclonal (clone 414-1) antibody recognizing the SARS-CoV-2 Spike S1 RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus. Molecular Weight: 141 kDa (full length S1 protein).

**<u>Purification</u>**: Protein A Chromatography.

<u>Background</u>: This antibody was derived from COVID-19 patients who have cleared the virus. Patient serum IgG was sequenced and expressed as full-length IgG1 with human immunoglobulin heavy and light chains in mammalian 293 cells.

<u>Application:</u> ELISA and neutralization assays.

### **Quality Assurance**



Log (Clone: 414-1 (BPS Bioscience #100793)), nM


**Fig.1** SARS-CoV-2 Spike RBD protein was coated onto microtiter plates at 0.5 μg/mL and then incubated with a dilution series of Spike S1 Neutralizing Antibody (SARS-CoV-2) (Clone: 414-1). Bound antibodies were detected with anti-human IgG conjugated to horseradish peroxidase (HRP) followed by incubation with HRP Substrate and then measuring the resulting absorbance at 450 nm.

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



6042 Cornerstone Court W, Ste B San Diego, CA 92121 **Tel:** 1.858.202.1401

Fax: 1.858.481.8694
Email: info@bpsbioscience.com



Log (Clone: 414-1 (BPS Bioscience #100793)), nM

Fig.2 Viral neutralization assays were performed with pseudotyped virus carrying a luciferase reporter gene and bearing the SARS-CoV-2 S1 spike glycoprotein. A549 lung epithelial target cells expressing the ACE2 receptor were incubated with virus and a graded dose of Spike S1 Neutralizing Antibody (SARS-CoV-2) (Clone: 414-1) Luciferase signal, indicative of cellular infection and viral gene expression, was measured. Viral neutralization by SARS-CoV-2 antibodies inhibits viral entry and, by extension, virus associated luciferase signal in manner proportional to antibody dose